Galderma has purchased full rights to distribute Valeant Pharmaceuticals's injectables Restylane, Perlane, Emervel, Sculptra, and Dysport for $1.4 billion. Two of the newly acquired fillers, Emervel Classic and Emervel Deep, have been submitted for approval by the FDA and Health Canada and are currently under review. Beginning July 28, Galderma will have a new branded distribution process and all accounts will automatically receive a new Galderma account number and information on the new ordering process. “We are pleased to complete the divestiture of our products to a company that is firmly committed to the aesthetic dermatology market," says J. Michael Pearson, chairman and CEO of Valeant. "Humberto Antunes, CEO of Galderma, has embraced our commercial team, and I know he will continue our efforts to build strong relationships with the healthcare leaders in this industry." Galderma is a pharmaceutical company specializing in the research, development and marketing of dermatological treatments. The expansion into aesthetic and corrective dermatology in the U.S. and Canada completes Galderma’s global skin health footprint and extends its leadership in aesthetic medicine worldwide.
the Latest Issue